Developer docs
API playgroundTry for free, no card

Search company profiles

Angelini Ventures

Full company profile

uuid0002ynu

Namestring
Angelini Ventures
Legal namestring
Angelini Ventures S.p.A.
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Angelini Ventures S.p.A. is the corporate venture capital arm of Angelini Industries, an Italian privately-held diversified industrial group headquartered in Rome. Founded in October 2022, the firm manages €300 million in committed capital for investments in BioTech and HealthTech companies globally, with a December 2025 partnership adding a further €150 million co-investment commitment from the European Investment Bank. The firm invests primarily in Series A and Series B rounds across Europe, North America, and Asia, with eight offices including a November 2025 Singapore regional headquarters. Its portfolio of 16+ companies spans gene therapy, antibody-drug conjugates, radiopharmaceuticals, brain monitoring, AI-powered care delivery, women's health, and CNS therapeutics.

The firm's core offering is its venture capital investment platform, augmented by an internally-developed AI-powered deal evaluation tool called "Investor Score" that applies statistical modeling and data-driven frameworks to startup selection. The firm operates two venture studios that create proprietary deal flow: Extend, a translational BRIDGE joint venture with Evotec and CDP Venture Capital developing drug discovery partnerships from Italian academic research, and Argobio, a European startup studio for biotech spinouts. The Angelini Lumira Bioscience Fund, a partnership with Lumira Partners, focuses specifically on early-stage CNS companies in North America. Portfolio outcomes to date include the $340 million ResMed acquisition of Noctrix Health in June 2026 (the firm's first exit), the FDA authorization of Noctrix's Nidra therapy for Restless Legs Syndrome, and measurable clinical outcomes from portfolio company Nobi (51% fall reduction in care facilities).

The firm generates returns through capital appreciation and exits from portfolio companies, with management fees funded by its €300 million Angelini Industries commitment. Over $80 million has been deployed across more than 10 new investments in the first two years of operation. Distribution is direct: the firm engages founders through active board representation, strategic guidance on clinical development, and network access across a global syndicate of co-investors. The team of approximately 11-50 professionals is led by CEO Paolo Di Giorgio and includes Managing Directors Elia Stupka, Tanja Dowe, and Regina Hodits, alongside senior investment, medical, data science, and operations leads.

Short descriptiontext

Angelini Ventures S.p.A. is Angelini Industries' corporate venture capital arm, deploying €300 million in BioTech and HealthTech Series A and B rounds globally. Founded in 2022, the firm operates eight offices and runs a proprietary AI-powered deal evaluation platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRome, Italy
HQ citystring
Rome
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, biotech investment, healthtech investment, healthcare venture capital, life sciences funding
Industry2 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • All Other Financial Investment Activities52399
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

Angelini Ventures generates returns through capital appreciation and exits from its portfolio companies. The firm invests €300 million globally in BioTech and HealthTech companies, targeting transformative healthcare innovations with potential for significant returns.

angeliniventures.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Angelini Ventures is the corporate venture capital arm of Angelini Industries, deploying €300 million globally into BioTech and HealthTech companies. It invests primarily in Series A and Series B rounds, taking active involvement alongside entrepreneurs to scale healthcare innovations across Europe, North America, and Asia. The firm also operates venture studios (Extend, Argobio) and runs a Fellows Program for MD/PhD candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 51% reduction in falls immediately after installation in care facilities using Nobi smart lamps
+2 more records
Product overview1 text field

Angelini Ventures is a venture capital firm that operates as a single unified investment platform under Angelini Industries, deploying €300 million globally across BioTech and HealthTech companies. The firm offers venture capital investment services as its core product, supplemented by two venture studio programs (Extend and Argobio) that identify and incubate early-stage biotechnology projects, and a Fellows Program providing venture capital internship opportunities for MD and PhD candidates. The investment platform focuses on Series A and Series B rounds in companies operating in digital health, life sciences, tech-enabled care delivery, and connected devices, with particular emphasis on CNS disorders, mental health, and segments targeting women, children, and the elderly.

Product and service5 records
1Angelini Ventures Investment Services
CategoryVenture Capital
2Extend Venture Studio
CategoryVenture Studio
3Argobio Venture Studio
CategoryVenture Studio
4Angelini Lumira Bioscience Fund
CategoryInvestment Fund
5Fellows Program
CategoryProgram
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-28
Description

Joint venture 'Extend' - translational BRIDGE partnership to develop drug discovery partnerships with Italian universities and research centers. Uses Evotec's technology platforms to accelerate translation of academic innovation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Government agency supporting Singapore biotech ecosystem development through partnership with Angelini Ventures Singapore office for early-stage venture investments.

3AI Singapore
Strategic tierMinorTypeStrategic or Co-development Partner
Description

National AI program partnering with Angelini Ventures Singapore office, leveraging AI-powered platform for investment decisions.

dealstreetasia.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Interdisciplinary research institute of Austrian Academy of Sciences committed to advancing understanding of human diseases through basic and biomedical research.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Open accelerator program offering tech startups pre-seed funding and tailored support to succeed and grow globally.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Digital Health Accelerator of CDP National Accelerators Network, born from initiative of CDP Venture Capital together with Healthware Group and Accelerace.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Leading Italian incubator and accelerator supporting launch and scale of digital and technology focused ventures.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Corporate venture arm of Boehringer Ingelheim investing in early-stage biotech, digital health, and preventive healthcare. Directly comparable to Angelini Ventures in corporate-backed healthcare VC focus, Elia Stupka previously worked at Boehringer Ingelheim Pharma.

TypeDirect peer
Description

Swiss-based corporate venture capital arm of Debiopharm focused on digital health and biotech early-stage investments. Highly comparable as both firms invest in Series A/B healthcare companies globally with active involvement; Tanja Dowe and Hamzeh Abdul Hadi both previously worked at Debiopharm Innovation Fund before joining Angelini Ventures.

TypeDirect peer
Description

Corporate venture arm of Roche investing in innovative therapeutic and diagnostic companies at early stages. Directly comparable as a global pharma corporate VC with Series A/B focus in biotech and healthtech, similar investment thesis and stage.

TypeDirect peer
Description

Italian venture capital asset management company with over €1.8B in AUM. Directly comparable as a co-investor and JV partner (Extend partnership) and as an Italian-headquartered active healthcare investor sharing the same geographic base and biotech ecosystem as Angelini Ventures.

TypeDirect peer
Description

Corporate venture capital arm of Novartis investing in early-stage biotech and digital health. Directly comparable to Angelini Ventures as a pharmaceutical corporate VC deploying capital into Series A/B therapeutic and digital health startups globally.

TypeDirect peer
Description

Corporate venture capital arm of Hikma Pharmaceuticals investing in digital health and therapeutics. Directly comparable as a Middle East-based pharma CVC; Hamzeh Abdul Hadi spent nearly six years at Hikma Ventures before joining Angelini Ventures as Senior Principal in Dubai.

TypeDirect peer
Description

Corporate venture capital arm of Sanofi investing in biotech and digital health startups. Comparable as a global pharma corporate VC with early-stage Series A/B focus across therapeutic areas overlapping with Angelini Ventures' portfolio.

TypeEmerging player
Description

European life sciences-focused venture capital firm where Managing Director Regina Hodits previously worked as Managing Partner. Comparable as a healthcare-specialized early-stage investor with portfolio overlap in CNS, oncology, and biotech; functions as both a peer and a relationship node for Angelini Ventures.

9Merck KGaA M Ventures
TypeDirect peer
Description

Corporate venture arm of Merck KGaA investing in early-stage biotech and technology platforms. Directly comparable as a global corporate VC with sector focus on life sciences and healthcare innovation at Series A/B stages.

10J&J Innovation (JJDC)
TypeDirect peer
Description

Venture arm of Johnson & Johnson investing across biotech, medical devices, and digital health globally. Comparable as a leading pharma corporate VC with broad healthcare mandate and significant capital deployment capabilities similar in scale and stage to Angelini Ventures.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment38 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Angelini Ventures

Healthcare Venture Capitalangeliniventures.com

Angelini Ventures S.p.A. is Angelini Industries' corporate venture capital arm, deploying €300 million in BioTech and HealthTech Series A and B rounds globally. Founded in 2022, the firm operates eight offices and runs a proprietary AI-powered deal evaluation platform.

What Angelini Ventures does

Angelini Ventures S.p.A. is the corporate venture capital arm of Angelini Industries, an Italian privately-held diversified industrial group headquartered in Rome. Founded in October 2022, the firm manages €300 million in committed capital for investments in BioTech and HealthTech companies globally, with a December 2025 partnership adding a further €150 million co-investment commitment from the European Investment Bank. The firm invests primarily in Series A and Series B rounds across Europe, North America, and Asia, with eight offices including a November 2025 Singapore regional headquarters. Its portfolio of 16+ companies spans gene therapy, antibody-drug conjugates, radiopharmaceuticals, brain monitoring, AI-powered care delivery, women's health, and CNS therapeutics.

The firm's core offering is its venture capital investment platform, augmented by an internally-developed AI-powered deal evaluation tool called "Investor Score" that applies statistical modeling and data-driven frameworks to startup selection. The firm operates two venture studios that create proprietary deal flow: Extend, a translational BRIDGE joint venture with Evotec and CDP Venture Capital developing drug discovery partnerships from Italian academic research, and Argobio, a European startup studio for biotech spinouts. The Angelini Lumira Bioscience Fund, a partnership with Lumira Partners, focuses specifically on early-stage CNS companies in North America. Portfolio outcomes to date include the $340 million ResMed acquisition of Noctrix Health in June 2026 (the firm's first exit), the FDA authorization of Noctrix's Nidra therapy for Restless Legs Syndrome, and measurable clinical outcomes from portfolio company Nobi (51% fall reduction in care facilities).

The firm generates returns through capital appreciation and exits from portfolio companies, with management fees funded by its €300 million Angelini Industries commitment. Over $80 million has been deployed across more than 10 new investments in the first two years of operation. Distribution is direct: the firm engages founders through active board representation, strategic guidance on clinical development, and network access across a global syndicate of co-investors. The team of approximately 11-50 professionals is led by CEO Paolo Di Giorgio and includes Managing Directors Elia Stupka, Tanja Dowe, and Regina Hodits, alongside senior investment, medical, data science, and operations leads.

Angelini Ventures firmographics

Firmographics
Name
Angelini Ventures
Legal name
Angelini Ventures S.p.A.
Website
https://angeliniventures.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Angelini Ventures S.p.A. is Angelini Industries' corporate venture capital arm, deploying €300 million in BioTech and HealthTech Series A and B rounds globally. Founded in 2022, the firm operates eight offices and runs a proprietary AI-powered deal evaluation platform.
Ownership category
akta.pro rank

Angelini Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
All Other Financial Investment Activities (52399), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital investing
  • Biotech investment
  • Healthtech investment
  • Healthcare venture capital
  • Life sciences funding

Where Angelini Ventures is headquartered

Location

Headquarters

HQ city
Rome
HQ country
Italy
HQ region
Europe

Offices8 records

Markets served

Angelini Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Investment Returns: Angelini Ventures generates returns through capital appreciation and exits from its portfolio companies. The firm invests €300 million globally in BioTech and HealthTech companies, targeting transformative healthcare innovations with potential for significant returns.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Angelini Ventures product offering

Product offering

Core offering

Angelini Ventures is the corporate venture capital arm of Angelini Industries, deploying €300 million globally into BioTech and HealthTech companies. It invests primarily in Series A and Series B rounds, taking active involvement alongside entrepreneurs to scale healthcare innovations across Europe, North America, and Asia. The firm also operates venture studios (Extend, Argobio) and runs a Fellows Program for MD/PhD candidates.

Product overview

Angelini Ventures is a venture capital firm that operates as a single unified investment platform under Angelini Industries, deploying €300 million globally across BioTech and HealthTech companies. The firm offers venture capital investment services as its core product, supplemented by two venture studio programs (Extend and Argobio) that identify and incubate early-stage biotechnology projects, and a Fellows Program providing venture capital internship opportunities for MD and PhD candidates. The investment platform focuses on Series A and Series B rounds in companies operating in digital health, life sciences, tech-enabled care delivery, and connected devices, with particular emphasis on CNS disorders, mental health, and segments targeting women, children, and the elderly.

Differentiator

Problem solved

Functional benefit

Products and services

  • Angelini Ventures Investment Services
  • Extend Venture Studio
  • Argobio Venture Studio
  • Angelini Lumira Bioscience Fund
  • Fellows Program

Quantifiable outcome

  • 51% reduction in falls immediately after installation in care facilities using Nobi smart lamps
  • +2 more outcomes

Companies that use Angelini Ventures

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles1 record

Angelini Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Angelini Ventures partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • EvoteccoreStrategic or Co-development Partner · 28 October 2022Joint venture 'Extend' - translational BRIDGE partnership to develop drug discovery partnerships with Italian universities and research centers. Uses Evotec's technology platforms to accelerate translation of academic innovation.
  • Enterprise SingaporeminorStrategic or Co-development PartnerGovernment agency supporting Singapore biotech ecosystem development through partnership with Angelini Ventures Singapore office for early-stage venture investments.
  • AI SingaporeminorStrategic or Co-development PartnerNational AI program partnering with Angelini Ventures Singapore office, leveraging AI-powered platform for investment decisions.
  • CEMMminorStrategic or Co-development PartnerInterdisciplinary research institute of Austrian Academy of Sciences committed to advancing understanding of human diseases through basic and biomedical research.
  • Imec IstartminorChannel Partner/ Reseller/ DistributorOpen accelerator program offering tech startups pre-seed funding and tailored support to succeed and grow globally.
  • Vita Digital Health AcceleratorminorChannel Partner/ Reseller/ DistributorDigital Health Accelerator of CDP National Accelerators Network, born from initiative of CDP Venture Capital together with Healthware Group and Accelerace.
  • Digital MagicsminorChannel Partner/ Reseller/ DistributorLeading Italian incubator and accelerator supporting launch and scale of digital and technology focused ventures.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Angelini Ventures competitors and assessment

Company assessment

Direct peers

  • Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim investing in early-stage biotech, digital health, and preventive healthcare. Directly comparable to Angelini Ventures in corporate-backed healthcare VC focus, Elia Stupka previously worked at Boehringer Ingelheim Pharma.
  • Debiopharm Innovation Fund: Swiss-based corporate venture capital arm of Debiopharm focused on digital health and biotech early-stage investments. Highly comparable as both firms invest in Series A/B healthcare companies globally with active involvement; Tanja Dowe and Hamzeh Abdul Hadi both previously worked at Debiopharm Innovation Fund before joining Angelini Ventures.
  • Roche Venture Fund: Corporate venture arm of Roche investing in innovative therapeutic and diagnostic companies at early stages. Directly comparable as a global pharma corporate VC with Series A/B focus in biotech and healthtech, similar investment thesis and stage.
  • CDP Venture Capital: Italian venture capital asset management company with over €1.8B in AUM. Directly comparable as a co-investor and JV partner (Extend partnership) and as an Italian-headquartered active healthcare investor sharing the same geographic base and biotech ecosystem as Angelini Ventures.
  • Novartis Venture Fund: Corporate venture capital arm of Novartis investing in early-stage biotech and digital health. Directly comparable to Angelini Ventures as a pharmaceutical corporate VC deploying capital into Series A/B therapeutic and digital health startups globally.
  • Hikma Ventures: Corporate venture capital arm of Hikma Pharmaceuticals investing in digital health and therapeutics. Directly comparable as a Middle East-based pharma CVC; Hamzeh Abdul Hadi spent nearly six years at Hikma Ventures before joining Angelini Ventures as Senior Principal in Dubai.
  • Sanofi Ventures: Corporate venture capital arm of Sanofi investing in biotech and digital health startups. Comparable as a global pharma corporate VC with early-stage Series A/B focus across therapeutic areas overlapping with Angelini Ventures' portfolio.
  • Merck KGaA M Ventures: Corporate venture arm of Merck KGaA investing in early-stage biotech and technology platforms. Directly comparable as a global corporate VC with sector focus on life sciences and healthcare innovation at Series A/B stages.
  • J&J Innovation (JJDC): Venture arm of Johnson & Johnson investing across biotech, medical devices, and digital health globally. Comparable as a leading pharma corporate VC with broad healthcare mandate and significant capital deployment capabilities similar in scale and stage to Angelini Ventures.

Emerging players

  • Wellington Partners Life Sciences: European life sciences-focused venture capital firm where Managing Director Regina Hodits previously worked as Managing Partner. Comparable as a healthcare-specialized early-stage investor with portfolio overlap in CNS, oncology, and biotech; functions as both a peer and a relationship node for Angelini Ventures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Angelini Ventures social profiles

Digital presence

Angelini Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Angelini Ventures leadership team

Management profile

Number of profiles

Profiles13 records

Angelini Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Angelini Ventures M&A and investment

M&A and investment

M&A

Investments38 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Angelini Ventures

What does Angelini Ventures do?

Angelini Ventures is the corporate venture capital arm of Angelini Industries, deploying €300 million globally into BioTech and HealthTech companies. It invests primarily in Series A and Series B rounds, taking active involvement alongside entrepreneurs to scale healthcare innovations across Europe, North America, and Asia. The firm also operates venture studios (Extend, Argobio) and runs a Fellows Program for MD/PhD candidates.

Is Angelini Ventures a public or private company?

Angelini Ventures is a private company. It is classified as corporate owned and is currently operating.

When was Angelini Ventures founded?

Angelini Ventures was founded in 2022. It employs 11 to 50 people.

Where is Angelini Ventures based?

Angelini Ventures is headquartered in Rome, Italy, in the Europe region.

How does Angelini Ventures make money?

One revenue line is on record: investment Returns.

Who are Angelini Ventures's main competitors?

Direct peers on record are Boehringer Ingelheim Venture Fund, Debiopharm Innovation Fund, Roche Venture Fund, CDP Venture Capital, Novartis Venture Fund, Hikma Ventures, Sanofi Ventures, Merck KGaA M Ventures and J&J Innovation (JJDC). Wellington Partners Life Sciences is listed as an emerging player.

Does Angelini Ventures have an API?

No public API is recorded for Angelini Ventures.

What industry is Angelini Ventures in?

Angelini Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52399 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyVectorY raises €83.5m to advance ALS gene therapyVectorY Therapeutics announced €74.5 million ($83.5 million) in new financing from Angelini Ventures, Invest-NL, and the European Investment Bank, alongside returning backers. The funding will advance its ALS gene therapy program.Global VenturingAngelini Ventures and M Ventures back €120m Nouscom cancer immunotherapy roundAngelini Ventures and M Ventures backed a €120m series D round for Swiss biotech Nouscom, co-led with Revelation Partners. The funds will advance its cancer-interception immunotherapy NOUS-209 into a global registration-enabling trial in Lynch syndrome patients. Long-term results from a Phase 1b/2 trial are due at the ESMO congress in Madrid on 25 October.The future of tradingAngelini Ventures backs Nouscom’s €120 million Series D roundNouscom raised €120 million in an oversubscribed Series D led by M Ventures and Revelation Partners, with Angelini Ventures participating. Proceeds will fund a global registration-enabling trial of its neoantigen-based immunotherapy NOUS-209 in Lynch syndrome, which holds FDA Fast Track designation. Long-term Phase 1b/2 data will be presented at ESMO in Madrid on October 25.FinSMEsMedical Microinstruments Raises $125M in Series D FundingMedical Microinstruments raised $125M in Series D financing led by BioStar Capital, with participation from S3 Ventures, Angelini Ventures, and an undisclosed strategic investor. The funds will expand business reach and advance clinical evidence for its Symani robotic microsurgery system, which has about 50 installed systems and 3,500 procedures worldwide.Startup BusinessAngelini Ventures e BEI guidano il round da 58 M$ di RougeTxAngelini Ventures and the European Investment Bank led a $58 million Series A round for RougeTx, a preclinical biotech developing disease-modifying therapies for rare vascular disorders. The funding will support RTX-001, targeting hereditary hemorrhagic telangiectasia, with no approved treatments currently. The investment is part of a €150 million partnership.The Pharma LetterRougeTx launches with $58 million to advance oral HHT candidate toward the clinicRougeTx launched with a $58 million Series A to advance RTX-001, a once-daily oral treatment for hereditary hemorrhagic telangiectasia. The round was co-led by BioGeneration Ventures with Angelini Ventures, the European Investment Bank, and others. The company has no approved therapies for HHT.Tech.euEuropean tech weekly recap: Over €1.7B invested across 70+ dealsOver 70 European tech funding deals worth more than €1.7 billion were tracked last week, with over 10 exits and M&A transactions. AI raised the most at €3 billion, followed by space and healthtech, while the UK led with €541.8 million.BeBeezAngelini Ventures e la BEI investono 17 mln di euro nei microstrumenti chirurgici di MMI - BeBeezAngelini Ventures and the European Investment Bank announced a €17 million co-investment in MMI, a medtech firm specializing in microsurgical robotics. This is the third investment in the partnership, with €48.5 million invested so far. Two more investments totaling €20 million are planned by year-end.Startup BusinessAngelini Ventures e BEI investono 17 milioni di euro in MMIAngelini Ventures and the European Investment Bank co-invested 17 million euros in MMI, a medtech firm developing robotic microsurgery systems. The investment is part of a 150 million euro partnership to fund European healthcare startups, with total commitments reaching 48.5 million euros so far. The partners plan to invest about 100 million euros by early 2027.AngeliniventuresEIB-Angelini Ventures Partnership Reaches €68.5 Million with New Investment in MMIAngelini Ventures and the EIB announced a €17 million co-investment in MMI, the developer of the Symani Surgical System. This is the third deal under their €150 million partnership, bringing total investments and commitments to €68.5 million, with about €100 million expected by early 2027.